Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04939701
Title Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

ovarian cancer

Advanced Solid Tumor

lung adenocarcinoma

melanoma

esophagus squamous cell carcinoma

lung non-small cell carcinoma

lung squamous cell carcinoma

myxoid liposarcoma

synovial sarcoma

Therapies

ASP0739 + Pembrolizumab

ASP0739

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.